Alnylam to Report New Patisiran and Revusiran Results at the XV International Symposium on Amyloidosis
June 27 2016 - 8:00AM
Business Wire
Company to Host Conference Call on Friday, July
1, 2016, at 8:30 am ET to Discuss Results
Alnylam Pharmaceuticals, Inc.
(Nasdaq:ALNY), the leading RNAi therapeutics company, announced
today that Alnylam scientists and collaborators will present
preliminary results from its ongoing Phase 2 open-label extension
(OLE) studies with patisiran and revusiran, investigational RNAi
therapeutics targeting transthyretin (TTR) for the treatment of
hereditary TTR-mediated amyloidosis (hATTR amyloidosis) at the XV
International Symposium on Amyloidosis (ISA) held July 3-7, 2016 in
Uppsala, Sweden.
All posters by Alnylam scientists and collaborators will be
presented during the poster session on July 4, 2016. Presentations
include:
- Phase 2 open-label extension study
of patisiran, an investigational RNAi therapeutic for the treatment
of hereditary ATTR amyloidosis with polyneuropathyAuthor:
Teresa Coelho, Hospital Santo Antonio, Centro Hospitalar do Porto,
Porto, Portugal
- Phase 2 open-label extension study
of revusiran, an investigational RNAi therapeutic for the treatment
of patients with transthyretin amyloidosis with cardiomyopathy:
Updated interim resultsAuthor: Julian D Gillmore, National
Amyloidosis Centre, UCL Medical School; London, United Kingdom
- Patisiran, an investigational RNAi
therapeutic for the treatment of hereditary ATTR amyloidosis with
polyneuropathy: Baseline demographics from the phase 3 APOLLO
studyAuthor: Ole B Suhr, Umeå University; Umeå, Sweden
- Relationship between TTR knockdown
and change in mNIS+7: Preliminary correlation findings from the
phase 2 open-label extension study of patisiran, an investigational
RNAi therapeutic for hereditary ATTR amyloidosis with
polyneuropathyAuthor: David Adams, CHU Bicêtre (APHP),
Université Paris-Sud; Paris, France
The Company will host a conference call on Friday, July 1,
2016, at 8:30am ET to discuss these results. To access
the call, please dial 877-312-7507 (domestic) or 631-813-4828
(international) five minutes prior to the start time and refer to
conference ID 36431889. A replay of the call will be available
beginning at 10:30 a.m. ET on July 1, 2016. To access the replay,
please dial 855-859-2056 (domestic) or 404-537-3406
(international), and refer to conference ID 36431889.
A live audio webcast of the call will be available on the
Investors section of the company's website, www.alnylam.com. An
archived webcast will be available on the Alnylam website
approximately two hours after the event.
About Alnylam Pharmaceuticals
Alnylam is a biopharmaceutical company developing novel
therapeutics based on RNA interference, or RNAi. The company is
leading the translation of RNAi as a new class of innovative
medicines. Alnylam’s pipeline of investigational RNAi therapeutics
is focused in 3 Strategic Therapeutic Areas (STArs): Genetic
Medicines, with a broad pipeline of RNAi therapeutics for the
treatment of rare diseases; Cardio-Metabolic Disease, with a
pipeline of RNAi therapeutics toward genetically validated,
liver-expressed disease targets for unmet needs in cardiovascular
and metabolic diseases; and Hepatic Infectious Disease, with a
pipeline of RNAi therapeutics that address the major global health
challenges of hepatic infectious diseases. In early 2015, Alnylam
launched its “Alnylam 2020” guidance for the advancement and
commercialization of RNAi therapeutics as a whole new class of
innovative medicines. Specifically, by the end of 2020, Alnylam
expects to achieve a company profile with 3 marketed products, 10
RNAi therapeutic clinical programs – including 4 in late stages of
development – across its 3 STArs. The company’s demonstrated
commitment to RNAi therapeutics has enabled it to form major
alliances with leading companies including Merck, Medtronic,
Novartis, Biogen, Roche, Takeda, Kyowa Hakko Kirin, Cubist,
GlaxoSmithKline, Ascletis, Monsanto, The Medicines Company, and
Sanofi Genzyme. In addition, Alnylam holds an equity position in
Regulus Therapeutics Inc., a company focused on discovery,
development, and commercialization of microRNA therapeutics.
Alnylam scientists and collaborators have published their research
on RNAi therapeutics in over 200 peer-reviewed papers, including
many in the world’s top scientific journals such as Nature, Nature
Medicine, Nature Biotechnology, Cell, New England Journal of
Medicine, and The Lancet. Founded in 2002, Alnylam maintains
headquarters in Cambridge, Massachusetts. For more information
about Alnylam’s pipeline of investigational RNAi therapeutics,
please visit www.alnylam.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160627005403/en/
Investors and Media:Alnylam Pharmaceuticals, Inc.Christine Regan
Lindenboom, 617-682-4340orInvestors:Josh Brodsky, 617-551-8276
Alnylam Pharmaceuticals (NASDAQ:ALNY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Alnylam Pharmaceuticals (NASDAQ:ALNY)
Historical Stock Chart
From Apr 2023 to Apr 2024